secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001628280-26-016400
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks
--------------------------------------------------------------------------------

- Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
- Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.
- Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.
- Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.
- FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/0001628280-26-016400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/skye-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer